'We're pretty cheap at the moment' - Cybin CEO Doug Drysdale

Cybin CEO Doug Drysdale talks to Jason Najum about transforming treatment of mental health disorders with psychedelics (0:45). CYB003, Phase 2 results for depression, moving into Phase 3 (3:00). How deuterated psilocin differentiates Cybin from competiton (10:00). IP and patents - critical to ROI (12:45). Esketamine and is JNJ's Spravato blazing a trail for psychedelics? (14:15) FDA challenges and Lykos lessons (21:20). Strong balance sheet will get it through Phase 3 data (25:50) Stock consolidation and attracting new buyers (30:35).<br /><br />Episode transcripts<br /><br />Show Notes:<br />Imran Khan On Psychedelics - More We Don't Know Than We Do<br />Psychedelic Stocks: Focus On Their Cash<br />FDA's MDMA...